Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Lung Fluid of Adults With and Without HIV Infection

Royal Liverpool University Hospital

Status and phase: Completed; Phase 4

Conditions: Meningitis; HIV; Pneumonia; Invasive Pneumococcal Disease

Treatments: Biological: 7-valent pneumococcal conjugate vaccine (Prevnar)

Study type: Interventional

Funder types: Other

Identifiers

NCT00371878

P99/00/102

P99/00/101

ISRCTN54494731

BAL0601

ISRCTN 061230

Details and patient eligibility

About

Lung immune responses are regulated independently of systemic responses. Injected vaccines may induce optimal responses in blood but not at mucosal surfaces. We compared the responses in serum and lung fluid to injected pneumococcal conjugate vaccine.

Full description

We tested the hypothesis that conjugate vaccine offered less protection against pneumonia due to a reduced mucosal response compared to serum. We further hypothesized that this response would be further compromised with HIV co-infection[32] due to lack of local CD4 lymphocyte support and an altered alveolar milieu. We measured pneumococcal capsular specific immunoglobulin responses to 7-valent conjugate vaccine in both lung fluid and serum from healthy HIV infected and uninfected volunteers, together with flow cytometric assessment of the relative numbers and phenotypes of BAL T lymphocyte, B lymphocyte and macrophages.

Sex: All

Ages: 17+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy volunteer adults

Exclusion criteria

• pregnant, recent illness, previous vaccination, asthma

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)